Lives unaffected by cystic fibrosis

DRUG DEVELOPMENT PIPELINE

Back to the Drug Development Pipeline

Lefamulin (XenletaTM)

Phase One

Phase One

Therapeutic Approach

Anti-Infective

Lefamulin (XenletaTM) is a compound that interferes with bacteria's ability to make protein, which is required for bacteria to grow. It is available in both oral and intravenouos (IV) formulations. Lefamulin is FDA-approved for the treatment of adults with community-acquired bacterial pneumonia (CABP). It is currently being studied for its safety and pharmacokinetics in fighting infections in people with CF.

Status

A phase 1 study to test the safety and pharmacokinetics of lefamulin in adults with CF is currently underway.

 

Sponsor

This program is sponsored by Nabriva. 



Contact us about Lefamulin (XenletaTM) >